Biofrontera Inc. (BFRIW)
| Market Cap | 23.62M +285.6% |
| Revenue (ttm) | 46.18M +13.7% |
| Net Income | -6.37M |
| EPS | -0.54 |
| Shares Out | 14.85M |
| PE Ratio | n/a |
| Forward PE | 10.27 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,294 |
| Open | 0.0260 |
| Previous Close | 0.0284 |
| Day's Range | 0.0250 - 0.0270 |
| 52-Week Range | 0.0201 - 0.1500 |
| Beta | 0.80 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About BFRIW
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
News
Biofrontera Earnings Call Transcript: Q2 2026
Q2 2026 saw record revenue growth of 33% year-over-year, gross margin expansion to 80%, and near-breakeven Adjusted EBITDA. Despite ITC restrictions on the XL lamp, a remediation plan is in place, and future growth is expected from new indications and label expansions.
Biofrontera Earnings release: Q2 2026
Biofrontera released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Biofrontera Quarterly report: Q2 2026
Biofrontera has published its Q2 2026 quarterly earnings report on August 13, 2026.
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of ...
Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz® (aminolevulinic acid hyd...
Biofrontera Transcript: AGM 2026
The meeting covered director elections, an incentive plan amendment, and auditor ratification, all of which were approved by shareholders. No questions were raised, and a quorum was confirmed with over 69% of eligible votes represented.
Biofrontera Transcript: Lytham Partners Spring 2026 Investor Conference
The company highlighted strong year-over-year revenue growth, improved gross margins, and a robust dermatology product pipeline. Key regulatory submissions are planned for 2026, targeting expanded indications and market share, with financials showing a path to break-even.
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of p...
Biofrontera Earnings Call Transcript: Q1 2026
Q1 2026 saw 17% revenue growth, gross margin expansion to 80%, and near-zero cash burn, reflecting the benefits of a new cost structure and strong commercial execution. Clinical pipeline advanced with FDA sNDA acceptance for SBCC and positive data in AK and acne.
Biofrontera Earnings release: Q1 2026
Biofrontera released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Biofrontera Quarterly report: Q1 2026
Biofrontera has published its Q1 2026 quarterly earnings report on May 14, 2026.
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis
The second annual #HatsonforAK Campaign runs May 18–24, 2026, culminating on Global Actinic Keratosis (AK) Awareness Day This social media–driven initiative invites people to wear a hat, share a photo...
Biofrontera Proxy statement: Proxy filing
Biofrontera filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Biofrontera Earnings Call Transcript: Q4 2025
Record 2025 revenues and Q4 profitability were driven by strong Ameluz sales, a transformative asset acquisition, and a new cost structure. Clinical pipeline advances and expanded IP position set the stage for margin expansion and growth in 2026.
Biofrontera Annual report: Q4 2025
Biofrontera has published its Q4 2025 annual report on March 19, 2026.
Biofrontera Earnings release: Q4 2025
Biofrontera released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company special...
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of...
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz ® PDT versus vehicle
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable
WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), tod...
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities
WOBURN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...
Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma
WOBURN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization and development of ...
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
WOBURN, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...
Biofrontera Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit
Biofrontera and LSL Pharma Group presented at the Lytham Partners 2026 Investor Healthcare Summit, outlining robust revenue growth, margin expansion, and strategic initiatives. Both companies are leveraging acquisitions, product innovation, and market expansion to drive future performance.
Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth
Fourth quarter results represent highest quarterly revenue in Company's history Q4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz ® Full year 2025 revenues also expected to sh...